NAC +taVNS in IDM Who Are Poor Oral Feeders

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-12

Study Completion Date

2024-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Infants of diabetic mothers who are failing to learn oral feeding by term age equivalence have greater CNS oxidative stress, which interact to predict poor neuroplasticity response to transcutaneous vagus nerve stimulation paired with oral feeding. We propose treating the oxidative stress in IDM infants prior to initiating taVNS, with an FDA-approved antioxidant (N-acetylcysteine, NAC) to improve CNS oxidative stress, which in turn regulates expression of many genes including BDNF, that may enhance motor learning.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

First-day High Dose Vitamin C, E in Severe Birth Asphyxia

NCT01743742

Birth Asphyxia

COMPLETED PHASE4

Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1

NCT04481035

Neurofibromatosis 1

COMPLETED PHASE2

Mechanisms and Management of Infant Dysphagia

NCT02583360

Dysphagia Airway Aspiration Airway Penetration

COMPLETED NA

Maternal B12 Supplementation to Improve Infant B12 Deficiency and Neurodevelopment

NCT03783104

Child Developmental Delay Child Malnutrition Maternal Exposure +1 more

UNKNOWN NA

Effects of Parenteral L-carnitine Supplementation in Premature Neonates

NCT00841295

Complication of Prematurity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Our group has recently conducted a first-in-infants pilot trial of pairing transcutaneous auricular vagus nerve stimulation (taVNS) with feeding to assist learning oromotor skills. We are enrolling preterm and HIE infants who are failing to learn oral feeds and clinically determined to need a G-tube. In preliminary data, taVNS paired with one or two daily feedings for 2 weeks resulted in 50% of infants attaining full feeds and avoiding G-tube.

A notable number of non-responders were infants of diabetic mothers (IDM) exposed to poor glucose control during pregnancy, all of whom required a G-tube. Uncontrolled maternal hyperglycemia is associated with increased systemic and neuro-inflammation, CNS oxidative stress, DNA damage, and worse neonatal outcomes compared to infants of euglycemic mothers. In neonatal animal models, hyperglycemia has been shown to decrease BDNF, alter long-term synaptogenesis and hippocampal neurochemistry, with ongoing CNS oxidative stress and inhibition of the cortical neuronal plasticity required for learning. In our pilot trial of taVNS-paired feeding, CNS glutathione concentrations (GSH), a MR spectroscopy (MRS) marker of oxidative stress, had significant interaction with IDM in predicting outcome, strongly suggesting that ongoing CNS oxidative stress contributes to neuropathology in IDMs failing oral feeding.

NAC is an FDA-approved antioxidant that is safe and crosses the blood brain barrier, increasing CNS GSH. NAC reduces CNS oxidative stress, enhances learning and provides a neuroprotective effect after brain injury in our and others neonatal HI and neuroinflammatory animal models. Both GSH and BDNF enhance neuroplasticity. Therefore, we hypothesize that pre-treatment with NAC in IDMs who are failing oral feeding, followed by taVNS-paired feeding, will decrease oxidative stress induced by maternal hyperglycemia and IDM-associated brain injury, and increase response to taVNS-paired feeding rehabilitation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infant of Diabetic Mother Oxidative Stress Vagus Nerve Stimulation Feeding Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

We will obtain parental consent, and then administer NAC 100mg/kg loading dose, followed by 75mg/kg q 6h via nasogastric tube, started 4 days prior to taVNS-paired feeding and continued for a total of 14 days. We will perform pharmacokinetics of oral NAC, and MRIs prior to, after 3-4 days of NAC, and after taVNS treatment period.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Co-investigator analyzing MRI data will be blinded to timing of MRI scan and dose

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NAC + taVNS

NAC will be given via nasogastric tube (n,g.) 100mg/kg loading dose, then 75mg/kg/dose n.g. q 6h, administered 1h before a feed, for a total of 14 days. taVNS will be administered to left ear during active sucking with 2 daily feedings starting after 4 days of NAC, continuing for 10 days.

Group Type EXPERIMENTAL

N acetyl cysteine + vagus nerve stimulation

Intervention Type COMBINATION_PRODUCT

NAC x 14 days, taVNS x 10 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

N acetyl cysteine + vagus nerve stimulation

NAC x 14 days, taVNS x 10 days

Intervention Type COMBINATION_PRODUCT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NAC, Acetadote, taVNS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infants of diabetic mothers who are failing oral feeding, \>39weeks gestation at enrollment, who are clinically stable, on minimal respiratory support (nasal cannula or room air), and clinical team has determined are G-tube candidates

Exclusion Criteria

* Unstable infants or those requiring positive pressure respiratory support
* Infants \<39 weeks gestation at enrollment
* Major unrepaired congenital anomalies or anomalies that limit feeding volumes
* Infants with cardiomyopathy
* Repeated episodes of autonomic instability (apnea/ bradycardia) not self resolving

Minimum Eligible Age

3 Weeks

Maximum Eligible Age

5 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No